| 1 |
34319769 | Breast Cancer Prevention: Time for Change. | 2021 Dec |
2 |
| 2 |
34402131 | Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor. | 2021 Nov |
10 |
| 3 |
32215462 | Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study. | 2020 Jan-Feb |
1 |
| 4 |
32257197 | Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer. | 2020 May |
1 |
| 5 |
29403307 | The effects of black cohosh on the regulation of estrogen receptor (ERα) and progesterone receptor (PR) in breast cancer cells. | 2018 |
1 |
| 6 |
29435103 | Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. | 2018 Jan 12 |
3 |
| 7 |
28100469 | Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. | 2017 Mar |
3 |
| 8 |
28122895 | 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. | 2017 Jan |
1 |
| 9 |
28415819 | Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. | 2017 May 2 |
2 |
| 10 |
28416639 | Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. | 2017 Nov |
3 |
| 11 |
28724391 | Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. | 2017 Jul 19 |
1 |
| 12 |
28969260 | Tamoxifen Induced Pancreatitis: An Unusual Complication of Commonly used Drug. | 2017 Aug |
1 |
| 13 |
28973704 | Neoadjuvant and Adjuvant Therapies for Breast Cancer. | 2017 Oct |
1 |
| 14 |
27116182 | Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. | 2016 May |
1 |
| 15 |
27417407 | An adaptive design for updating the threshold value of a continuous biomarker. | 2016 Nov 30 |
1 |
| 16 |
27722840 | Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. | 2016 Nov |
6 |
| 17 |
29924509 | [Advances in the research of pharmacogenomics of tamoxifen]. | 2016 Sep |
2 |
| 18 |
24469035 | Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. | 2015 Jan 22 |
1 |
| 19 |
25961581 | Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment. | 2015 |
2 |
| 20 |
25971350 | ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer. | 2015 May 15 |
2 |
| 21 |
26214623 | Breast cancer in postmenopausal patients: Impact of age. | 2015 May-Jun |
3 |
| 22 |
24606123 | Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. | 2014 Apr |
1 |
| 23 |
24715381 | Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. | 2014 May |
1 |
| 24 |
25276378 | The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. | 2014 Sep |
1 |
| 25 |
25337220 | Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy. | 2014 |
1 |
| 26 |
26327832 | Tamoxifen-induced acute pancreatitis - a case report. | 2014 Mar |
1 |
| 27 |
23242584 | Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. | 2013 Jan |
8 |
| 28 |
23314808 | Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines. | 2013 Mar |
1 |
| 29 |
23836010 | A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. | 2013 Jul |
2 |
| 30 |
23972025 | Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort. | 2013 |
1 |
| 31 |
24345432 | Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. | 2013 Dec 17 |
3 |
| 32 |
24649292 | Differences in estrogen and progesterone receptor expression in endometrial polyps and atrophic endometrium of postmenopausal women with and without exposure to tamoxifen. | 2013 Nov |
1 |
| 33 |
22266527 | Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. | 2012 Apr |
1 |
| 34 |
22548922 | A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. | 2012 May 1 |
1 |
| 35 |
22711706 | A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. | 2012 Aug 15 |
2 |
| 36 |
22738860 | Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. | 2012 Dec |
2 |
| 37 |
23091541 | Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. | 2012 Sep |
1 |
| 38 |
20133149 | Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? | 2011 Feb |
4 |
| 39 |
20953835 | Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. | 2011 Aug |
2 |
| 40 |
21327800 | Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. | 2011 Jul |
3 |
| 41 |
21339261 | A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. | 2011 |
2 |
| 42 |
21421521 | Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. | 2011 Mar |
2 |
| 43 |
21734071 | Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. | 2011 Oct |
1 |
| 44 |
21826535 | A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen. | 2011 Oct |
1 |
| 45 |
22046795 | [Expression of hormonal receptors (alpha-estrogen, beta-estrogen, progesteron), Ki-67 and P53 in endometrium of tamoxifen treated breast cancer patients]. | 2011 Jul-Sep |
1 |
| 46 |
19205877 | Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. | 2010 Jan |
4 |
| 47 |
19858087 | Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. | 2010 May |
1 |
| 48 |
19924529 | Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. | 2010 Oct |
3 |
| 49 |
20179226 | Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. | 2010 Mar 1 |
1 |
| 50 |
20550710 | The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. | 2010 Jun 15 |
1 |